CDBIO(SH:688739) Xin Lang Zheng Quan·2025-10-27 01:27Core Viewpoint - Chengda Biological experienced a slight decline of 0.18% in stock price on October 24, with a trading volume of 50.58 million yuan, indicating a high level of market activity and investor interest [1] Financing Summary - On October 24, Chengda Biological had a financing buy-in amount of 7.48 million yuan and a financing repayment of 6.40 million yuan, resulting in a net financing buy of 1.08 million yuan [1] - As of October 24, the total financing and securities lending balance for Chengda Biological was 258 million yuan, with the financing balance at 257 million yuan, accounting for 2.26% of the circulating market value, which is above the 80th percentile of the past year [1] - The company repaid 2,400 shares in securities lending and sold 1,400 shares on October 24, with a selling amount of 38,300 yuan, while the securities lending balance was 1.0685 million yuan, exceeding the 90th percentile of the past year [1] Business Performance Summary - As of June 30, Chengda Biological had 25,300 shareholders, a decrease of 0.42% from the previous period, with an average of 16,431 circulating shares per person, an increase of 121.52% [2] - For the first half of 2025, the company reported an operating income of 707 million yuan, a year-on-year decrease of 19.75%, and a net profit attributable to the parent company of 122 million yuan, down 44.47% year-on-year [2] - Since its A-share listing, Chengda Biological has distributed a total of 1.492 billion yuan in dividends, with 1.075 billion yuan distributed over the past three years [2] Shareholding Structure Summary - As of June 30, 2025, the top ten circulating shareholders included Southern CSI 1000 ETF, which held 1.9087 million shares, an increase of 357,200 shares from the previous period [2] - Hong Kong Central Clearing Limited was the fifth largest circulating shareholder with 1.9033 million shares, a decrease of 509,000 shares [2] - Other notable changes included a decrease in holdings for Bosera SSE STAR 100 ETF and an increase for CSI 1000 ETF, indicating shifts in institutional investment [2]